Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial

Nature Communications(2024)10.1038/s41467-024-50880-2Source: DataRank Database

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial is a research paper published in Nature Communications (2024). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 5.53)OA: goldTopics (68)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

Lin Wang ORCID,Tiantian Zhang ORCID,Soung-chul Cha,Joo Y. Song ORCID,Zhenyuan Dong ORCID

Live enrichment

PubMed:39128904 PMC:PMC11317512 OpenAlex:https://openalex.org/W4401496422

NCI NIH HHS

Grant: P30 CA033572

NCI NIH HHS

Grant: P50 CA107399

National Institutes of Health

Grant: 5P30CA033572-27

Developmental Funds

National Institutes of Health

Grant: 5P50CA107399-14

City of Hope Lymphoma SPORE

FWCI

5.53

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.nature.com/articles/s41467-024-50880-2.pdf

publisherhttps://www.nature.com/articles/s41467-024-50880-2.pdf

publisherhttps://www.nature.com/articles/s41467-024-50880-2

journalhttps://doi.org/10.1038/s41467-024-50880-2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39128904

Fields of Study

Chronic Lymphocytic Leukemia ResearchImmunotherapy and Immune ResponsesImmune Cell Function and InteractionMedicine0301 basic medicine03 medical and health sciences0303 health sciencesHumansMaleCancer VaccinesMiddle AgedFemaleWaldenstrom MacroglobulinemiaAgedTumor MicroenvironmentPrecision MedicineVaccines, DNAAntigens, NeoplasmB-Lymphocytes

MeSH Terms

AgedAntigens, NeoplasmB-LymphocytesFemaleHumansWaldenstrom MacroglobulinemiaMaleMiddle AgedVaccines, DNACancer VaccinesPrecision MedicineTumor Microenvironment

Keywords

Lymphoplasmacytic LymphomaRandomized controlled trialMedicineIntervention (counseling)LymphomaImmunologyInternal medicineWaldenstrom macroglobulinemiaMale570Medical SciencesBioinformaticsScience610DiseasesCancer VaccinesArticleBiomedical InformaticsHemic and Lymphatic DiseasesAntigens, NeoplasmNeoplasmsMedical SpecialtiesMedicine and Health SciencesTumor MicroenvironmentVaccines, DNAHumansAntigensPrecision MedicineAgedVaccinesB-LymphocytesQDNAMiddle AgedOncologyNeoplasmFemale

Sustainable Development Goals

SDG 3: 3. Good health